Renaissance Capital logo

NLS Pharmaceutics Priced, Nasdaq: NLSP

Developing controlled-release formulations of approved drugs for ADHD and narcolepsy.

Industry: Health Care

Latest Trade: $1.41 0.00 (0.0%)

First Day Return: -30.4%

Return from IPO: -65.9%

Industry: Health Care

We are an innovative biopharmaceutical company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. According to the World Health Organization and based on data from the Global Burden of Disease Report, 25% of the world’s population suffers from at least one CNS disorder, resulting in a socio-economic burden of more than $317 billion annually in the United States alone. Additionally, CNS disorders are expected to account for approximately 15% of the global disease burden by 2020, the largest burden of any disease area. However, treatment options for these conditions are often limited, inadequate or nonexistent, and the development of new CNS treatments generally trails behind other therapeutic areas. We are pursuing the development of the next generation of CNS therapies with high medical impact to address this critical and growing unmet need.
more less
IPO News for NLS Pharmaceutics
more
IPO Data
IPO File Date 02/28/2020
Offer Price $4.15
Price Range $5.00 - $6.00
Offer Shares (mm) 4.8
Deal Size ($mm) $20
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/28/2021
Offer Price $4.15
Price Range $5.00 - $6.00
Offer Shares (mm) 4.8
Deal Size ($mm) $20
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Stans, Switzerland
Founded 2015
Employees 5
Website www.nlspharma.com